Tags

Type your tag names separated by a space and hit enter

miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
Oncol Rep. 2016 Dec; 36(6):3552-3558.OR

Abstract

Epithelial ovarian cancer (EOC) is one of the malignant tumors that seriously affects women's health and chemotherapy resistance is an important reason for the poor prognosis. The present study was conducted to investigate whether microRNA-100 (miR-100) can be used to modulate the tolerance to cisplatin in EOC. Expression of miR-100 was compared between ovarian cancer cells tolerant and not tolerant to cisplatin. Mimic and antisense were used to study the roles and related mechanisms of miR-100 in cisplatin sensitivity in EOC. The alternation in the cisplatin sensitivity was investigated using grafted tumors derived from SKOV3/DDP cells with upregulated or downregulated miR-100 expression. miR-100 was lower in cisplatin resistant cell line SKOV3/DDP than in cisplatin sensitive cell line SKOV3. miR-100 might increase cisplatin sensitivity by inhibiting cell proliferation and conversion from G1 to S phase and increasing apoptosis. We showed that mTOR and PLK1 are targets of miR-100 and the cells were resensitized probably due to targeted downregulation of mTOR and PLK1 by miR-100. In vivo study with nude mice showed that tumors derived from miR-100 mimic-transfected cells were more sensitive to cisplatin and had reduced expression of mTOR and PLK1. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin probably by inhibiting cell proliferation, inducing apoptosis and arresting cell cycle and by targeted downregulation of mTOR and PLK1 expression.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Zhongshan People's Hospital, Zhongshan, Guangdong 528403, P.R. China.Department of Obstetrics and Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.Department of Obstetrics and Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.Department of Obstetrics and Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27748936

Citation

Guo, Peng, et al. "MiR-100 Resensitizes Resistant Epithelial Ovarian Cancer to Cisplatin." Oncology Reports, vol. 36, no. 6, 2016, pp. 3552-3558.
Guo P, Xiong X, Zhang S, et al. MiR-100 resensitizes resistant epithelial ovarian cancer to cisplatin. Oncol Rep. 2016;36(6):3552-3558.
Guo, P., Xiong, X., Zhang, S., & Peng, D. (2016). MiR-100 resensitizes resistant epithelial ovarian cancer to cisplatin. Oncology Reports, 36(6), 3552-3558. https://doi.org/10.3892/or.2016.5140
Guo P, et al. MiR-100 Resensitizes Resistant Epithelial Ovarian Cancer to Cisplatin. Oncol Rep. 2016;36(6):3552-3558. PubMed PMID: 27748936.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin. AU - Guo,Peng, AU - Xiong,Xiangpeng, AU - Zhang,Sainan, AU - Peng,Dongxian, Y1 - 2016/10/03/ PY - 2016/05/04/received PY - 2016/09/05/accepted PY - 2016/10/18/pubmed PY - 2017/3/18/medline PY - 2016/10/18/entrez SP - 3552 EP - 3558 JF - Oncology reports JO - Oncol. Rep. VL - 36 IS - 6 N2 - Epithelial ovarian cancer (EOC) is one of the malignant tumors that seriously affects women's health and chemotherapy resistance is an important reason for the poor prognosis. The present study was conducted to investigate whether microRNA-100 (miR-100) can be used to modulate the tolerance to cisplatin in EOC. Expression of miR-100 was compared between ovarian cancer cells tolerant and not tolerant to cisplatin. Mimic and antisense were used to study the roles and related mechanisms of miR-100 in cisplatin sensitivity in EOC. The alternation in the cisplatin sensitivity was investigated using grafted tumors derived from SKOV3/DDP cells with upregulated or downregulated miR-100 expression. miR-100 was lower in cisplatin resistant cell line SKOV3/DDP than in cisplatin sensitive cell line SKOV3. miR-100 might increase cisplatin sensitivity by inhibiting cell proliferation and conversion from G1 to S phase and increasing apoptosis. We showed that mTOR and PLK1 are targets of miR-100 and the cells were resensitized probably due to targeted downregulation of mTOR and PLK1 by miR-100. In vivo study with nude mice showed that tumors derived from miR-100 mimic-transfected cells were more sensitive to cisplatin and had reduced expression of mTOR and PLK1. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin probably by inhibiting cell proliferation, inducing apoptosis and arresting cell cycle and by targeted downregulation of mTOR and PLK1 expression. SN - 1791-2431 UR - https://www.unboundmedicine.com/medline/citation/27748936/miR_100_resensitizes_resistant_epithelial_ovarian_cancer_to_cisplatin_ L2 - http://www.spandidos-publications.com/or/36/6/3552 DB - PRIME DP - Unbound Medicine ER -